The past 12 months have exciting at Safeguard Scientifics. In December of 2010, partner companies Clarient and Avid Radiopharmaceuticals were both acquired by giants in…
Posted by
In the latest VentureView report, the National Venture Capital Association and Dow Jones & Co. reported that 63 percent of VCs think their portfolio companies…
Posted by
There is no question that technology innovations will continue to revolutionize the way we work and play in 2012 and beyond. The Internet opens up…
Posted by
Last week, I sat on a panel session at the IMPACT 2011 Venture Summit Mid-Atlantic conference held by the Greater Philadelphia Alliance for Capital and Technologies (PACT)…
Posted by
Contrary to popular belief, a startup’s success does not solely hinge on the idea, but the leadership and talent that drive the company forward. For…
Posted by
Safeguard Scientifics has a unique and consistent approach to putting capital to work in the life sciences sector. We target capital efficient diagnostic companies that…
Posted by
PixelOptics’ emPower! eyewear is the world’s first and only electronic focusing eyeglasses—focusing faster than the blink of an eye. The technology is embedded inside the lenses and…
Posted by
The convergence between life sciences and technology cannot be ignored. That’s why at Safeguard Scientifics, we consolidated of our life sciences and technology deal teams.…
Posted by
Ninety percent of migraine sufferers experience nausea, while 60 percent experience vomiting because of their migraine. As a result, today’s most common migraine treatments that…
Posted by
